IQV IQVIA HOLDINGS INC.
Company Analysis
Latest News
IQVIA Announces Pricing of $2 Billion Senior Notes Offering to Refinance Debt
IQVIA Holdings Inc. announced the pricing of a $2 billion senior notes offering by its wholly owned subsidiary, IQVIA Inc. The proceeds from this offering are...
🟢 IQVIA is trading 4.3% up in after-hours trading amid planned $2 billion senior-notes offering
IQVIA is trading $267.96 (+4.28%) amid its announcement of a planned $2 billion senior-notes offering due 2034; the financing is not explicitly linked to the...
IQVIA Target Raised to $300 by HSBC, Institutional Interest Grows
HSBC raised its price target for IQVIA Holdings Inc. to $300 from $280. The investment bank maintained its Buy rating on the stock. Institutional investors...
Cantillon Capital Exits $292M IQVIA (IQV) Position
William Von Mueffling's Cantillon Capital Management fully exited its stake in IQVIA Holdings (IQV), selling all 1.71 million shares. The position was valued...
IQVIA Secures $3 Billion Investment From BlackRock and Deutsche Bank
IQVIA Holdings (IQV) attracted major institutional investments from BlackRock Inc. and Deutsche Bank AG. SEC 13F filings reported on August 20, 2026, disclosed...
🟢 IQVIA is trading 4.1% up today as healthcare stocks rallied broadly
IQVIA is trading 4.1% up at $259.51 after healthcare stocks rallied broadly on improving earnings expectations, attractive valuations, and investor rotation...
🟢 IQVIA rises 4.1% — Healthcare Stocks Surge on Strong Earnings Outlook and Investor Rotation
With Healthcare (XLV) up 3.2%, this looks like a sector-led move rather than a company-specific surprise. The healthcare sector experienced a significant...
🔴 IQVIA is trading 17.84% down in after-hours trading with no clear catalyst identified
IQVIA is trading $198.52 (-17.84%) after an unexplained August 13, 2026 after-hours decline. • No credible August 13 company-specific catalyst was identified...
🔴 IQVIA is trading 15.1% down in after-hours trading with no clear catalyst identified
IQVIA is trading 15.14% down at $205.15 in after-hours trading after an unexplained August 12, 2026 decline with no clear catalyst identified. - No credible...
🔴 IQVIA is trading 14% down in after-hours trading with no clear catalyst identified
IQVIA is trading 14% down at $209.66 after an unexplained August 11, 2026 after-hours drop from the provided regular-session close of $243.90. - Searches...
🟢 IQVIA is trading 4% up today following multiple analyst upgrades and sector strength
IQVIA is trading 4% up today at $237.42 following a wave of analyst price-target upgrades and broader strength in the healthcare sector. • Argus, Evercore...
🔴 IQVIA is trading 4% down today on profit-taking after a sharp post-earnings rally
IQVIA is trading 4% down at $237.95 as investors lock in gains following a significant 25% five-day advance triggered by its July 28 earnings beat and guidance...
🟢 IQVIA is trading 15.37% up today after Q2 earnings beat and raised full-year guidance
IQVIA is trading 15.37% up at $246.45 after beating Q2 2026 earnings estimates and raising its full-year outlook. • The company reported $4.37 billion in...
🟢 IQVIA is trading 10.21% up today after Q2 earnings beat and raised guidance
IQVIA is trading at $235.00 (+10.21%) following a strong Q2 2026 earnings beat and an upward revision to its full-year outlook. • The company reported revenue...
IQVIA Smashes Q2 Estimates With Record Bookings — But Can a Clinical Trials Giant Trading Near Its 52-Week High Sustain the Momentum?
Shares surged +7.9% to $230.01 in pre-market after IQVIA reported second-quarter revenue of $4.37 billion and adjusted earnings of $3.15 per share — both...
🟢 IQVIA is trading 7.9% up today after beating Q2 estimates and raising full-year guidance
IQVIA is trading at $230.01 (+7.87%) in pre-market after reporting second-quarter results that beat estimates and lifting its full-year 2026 guidance. • The...
IQVIA's second quarter results beat estimates on strong R&D bookings, prompting a full-year 2026 guidance raise.
IQVIA reported second quarter 2026 revenue of $4.37 billion and adjusted EPS of $3.15, beating analyst estimates of $4.31 billion and $3.02, respectively. The...
IQVIA Holdings Inc Q2 2026 Earnings Preview: What Analysts Expect on July 28, 2026
IQVIA Holdings Inc (IQV) is expected to report Q2 2026 revenue of $4.31 billion and adjusted EPS of $3.02, while currently trading at $209.41 relative to an...
IQVIA's first quarter 2026 revenue grew 8.4% to $4.15B, beating estimates and leading to a raised full-year EPS outlook.
IQVIA reported first quarter 2026 revenue of $4.151 billion, an increase of 8.4% year-over-year, and adjusted EPS of $2.90, up 7.4% from the prior year. Both...
IQVIA Holdings Inc Q1 2026 Earnings Preview: What Analysts Expect on May 05, 2026
Wall Street expects IQVIA Holdings Inc to report Q1 2026 revenue of approximately $4.10 billion and earnings per share of $2.51, with the current stock price...